$SMMT To Dr. Julie Brahmer. Regarding to your not professional concern on Harmoni-6's elderly subgroup, I now post some well-know trials' subgroup data and you and your blind supporters will realize how arrogant and ignorant your comments were at the ASCO
In keynote-407 Keytruda also "missed" subgroup analysis in age group>=65. Does it affect overall efficacy for elderly? No, it suggested nothing as this was just noise caused by imbalance of baseline situations. Once the drug has enough pooled data across many trials the meta analyses of subgroups become meaningful.
Brahmer's concern about age band 65-74 is absurd. This is not even a preset subgroup, not randomized, not double blinded, the baseline situations in two arms could be totally different. She sounds biased and nitpicking. She can even challenge "patient subgroup that wearing glasses" or "patient subgroup with taller stature"
$SMMT Man, what can i say…It's landslide win versus PD-1. No doubt AK112 is becoming the new king of immunotherapy. Congratulations Summit Therapeutics and Akeso!
@jimcramer You can ask gemini to generate a comprehensive report on this cult stock. Basically it makes perfect sense on every point that this stock will crash 50-80% in the near future.
@RealMattMoney@PalantirTech Nah, it has not much to do with palantir. It was CIA’s infiltration work. CIA has spent $50million to corrupt Venezuela’s officials and managed to gain the insider intelligence
@anammostarac Nah, it has not much to do with palantir. It was CIA’s infiltration work. CIA has spent $50million to corrupt Venezuela’s officials and managed to gain the insider intelligence.
@alifarhat79 Nah, it has not much to do with palantir. It was CIA’s infiltration work. CIA has spent $50million to corrupt Venezuela’s officials and managed to gain the insider intelligence